Somewhat Favorable News Coverage Somewhat Unlikely to Impact Masimo (NASDAQ:MASI) Share Price

Media coverage about Masimo (NASDAQ:MASI) has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Masimo earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 46.5830118034585 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the headlines that may have impacted Accern’s rankings:

Masimo (NASDAQ MASI) opened at $88.11 on Wednesday. Masimo has a twelve month low of $60.31 and a twelve month high of $104.71. The stock has a market capitalization of $4,571.35, a P/E ratio of 33.90, a price-to-earnings-growth ratio of 2.98 and a beta of 0.72.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.17. The company had revenue of $193.69 million for the quarter, compared to analyst estimates of $189.01 million. Masimo had a return on equity of 22.17% and a net margin of 45.83%. Masimo’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.52 earnings per share. equities analysts forecast that Masimo will post 2.95 EPS for the current year.

Several research analysts have commented on MASI shares. BTIG Research raised Masimo from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Monday, August 14th. Stifel Nicolaus restated a “buy” rating and set a $108.00 price target on shares of Masimo in a report on Friday, November 3rd. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a report on Thursday, November 2nd. Finally, BidaskClub cut Masimo from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $97.17.

In other news, Director Steven Barker sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total transaction of $900,000.00. Following the completion of the sale, the director now directly owns 73,249 shares of the company’s stock, valued at approximately $6,592,410. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Yongsam Lee sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $89.89, for a total value of $449,450.00. Following the sale, the executive vice president now directly owns 74,000 shares of the company’s stock, valued at $6,651,860. The disclosure for this sale can be found here. Insiders sold a total of 53,074 shares of company stock valued at $4,737,245 over the last three months. 13.10% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co. and related companies with's FREE daily email newsletter.

Leave a Reply